Read further: Targeting CA12 to Mitigate Doxorubicin-Induced Cardiotoxicity: Insights from CRISPR Screens and Drug Discovery
VISUALIZED: Targeting CA12 to Mitigate Doxorubicin-Induced Cardiotoxicity: Insights from CRISPR Screens and Drug Discovery
You may also like
Repurposing GLP-1 Drugs to Improve Myocardial...
Mechanisms of Viral-Induced Myocardial Injury in...
Cardiovascular Stress and Autonomic Activation...
Safety and Efficacy of Non-Pharmacological RIC in...
Impact of Host Blood Flow on Bacterial Communication...
Therapeutic Potential of PGG in the Clearance of...
About the author
